Epigenetic Mechanisms in Hepatic Stellate Cell Activation During Liver Fibrosis and Carcinogenesis
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Liver fibrosis is an essential component of chronic liver disease (CLD) and hepatocarcinogenesis. The fibrotic stroma is a consequence of sustained liver damage combined with exacerbated extracellular matrix (ECM) accumulation. In this context, activation of hepatic stellate cells (HSCs) plays a key role in both initiation and perpetuation of fibrogenesis. These cells suffer profound remodeling of gene expression in this process. This review is focused on the epigenetic alterations participating in the transdifferentiation of HSCs from the quiescent to activated state. Recent advances in the field of DNA methylation and post-translational modifications (PTM) of histones (acetylation and methylation) patterns are discussed here, together with altered expression and activity of epigenetic remodelers. We also consider recent advances in translational approaches, including the use of epigenetic marks as biomarkers and the promising antifibrotic properties of epigenetic drugs that are currently being used in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functions of DNA methylation: islands, start sites, gene bodies and beyond
Jones, P. A. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3230 · Cited by 6,061
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842 · cited 4×
“Therefore, following liver injury, HSCs become activated, acquiring a phenotype characterized by the loss of retinoid droplets, increased proliferation and contractile activity, and the release of proinflammatory, profibrogenic, and promitogenic cytokines [8,10,13].”
BackgroundInfluentialGenomic DNA methylation: the mark and its mediators.
Klose, R. J., & Bird, A. P. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.12.008 · Cited by 2,501 · cited 1×
“, MeCP2, MBD1-4, and Kaiso) along with their associated complexes [20].”
BackgroundPathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
Michalopoulos, G. K. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21172 · Cited by 1,384 · cited 2×
“However, hepatic stellate cell (HSC) activation remains the most dominant pathway to produce the ECM necessary to allow the restoration of damaged liver mass [7,8,11] and constitutes the leading cause of hepatic fibrosis perpetuation [12].”
BackgroundHistone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206 · cited 1×
“They are currently licensed for the treatment of different malignancies and are being explored as therapies for many other tumors [90].”
BackgroundGene Body Methylation Can Alter Gene Expression and Is a Therapeutic Target in Cancer
Yang, X., Han, H., De Carvalho, D. D., Lay, F. D., Jones, P. A., & Liang, G. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.028 · Cited by 1,199 · cited 1×
“Recent studies also suggest that depending on their location and density along the structure of genes, they might also be acting as activating marks [21,22], as methylation in gene bodies and at CpG-poor sites have been observed in active genes [23].”
BackgroundDNA methylation pathways and their crosstalk with histone methylation
Du, J., Johnson, L. M., Jacobsen, S. E., & Patel, D. J. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4043 · Cited by 1,000 · cited 1×
“Nevertheless, it has become apparent that depending on the DNA sequence context DNMT1 can display de novo activity, while DNMT3A and DNMT3B may participate in maintenance methylation [27,28].”
BackgroundMeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system
Mellén, M., Ayata, P., Dewell, S., Kriaucionis, S., & Heintz, N. (2012) · Cell · doi:10.1016/j.cell.2012.11.022 · Cited by 943
Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis
Kisseleva, T., Cong, M., Paik, Y., Scholten, D., Jiang, C., Benner, C., Iwaisako, K., Moore-Morris, T., Scott, B., Tsukamoto, H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201840109 · Cited by 805
Hepatic stellate cells in liver development, regeneration, and cancer
Yin, C., Evason, K. J., Asahina, K., & Stainier, D. Y. R. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66369 · Cited by 719 · cited 1×
“HSCs undergo a drastic phenotypic change to become myofibroblasts [14], involving extensive changes in gene expression.”
BackgroundDeactivation of Hepatic Stellate Cells During Liver Fibrosis Resolution in Mice
Troeger, J. S., Mederacke, I., Gwak, G., Dapito, D. H., Mu, X., Hsu, C. C., Pradere, J., Friedman, R. A., & Schwabe, R. F. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.036 · Cited by 515
Peroxisome proliferator-activated receptors and hepatic stellate cell activation
Miyahara, T., Schrum, L., Rippe, R., Xiong, S., Yee, H. F., Motomura, K., Anania, F. A., Willson, T. M., & Tsukamoto, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006577200 · Cited by 473 · cited 1×
“PPARγ reinforces their adipogenic phenotype, but when HSCs become activated, PPARγ expression and activity are downregulated [70,71].”
BackgroundMeCP2 Controls an Epigenetic Pathway That Promotes Myofibroblast Transdifferentiation and Fibrosis
Mann, J., Chu, D. C. K., Maxwell, A., Oakley, F., Zhu, N., Tsukamoto, H., & Mann, D. A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.10.002 · Cited by 397 · cited 18×
“Abbreviations CLD Chronic Liver Disease ECM Extracellular Matrix HSCs Hepatic Stellate Cells DNA Deoxyribonucleic Acid PTM Postranslational Modifications HCC Hepatocellular Carcinoma CpG Cytosine Guanine Dinucleotide MeCP2 Methyl-CpG-Binding Domain Protein 2 MBD1-4 Methyl-CpG-Binding Domain Protein 1-4 DNMTs DNA-Methy…”
BackgroundInfluentialRelationship Between Methylome and Transcriptome in Patients With Nonalcoholic Fatty Liver Disease
Murphy, S. K., Yang, H., Moylan, C. A., Pang, H., Dellinger, A., Abdelmalek, M. F., Garrett, M. E., Ashley–Koch, A., Suzuki, A., Tillmann, H. L., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.07.047 · Cited by 391 · cited 1×
“They found that DNA methylation status at specific CpGs might be useful for predicting progression of the disease and development of fibrosis, further supporting their previous studies on DNA methylome signatures and NAFLD patient’s stratification [83].”
ResultDou, C., Liu, Z., Tu, K., Zhang, H., Chen, C., Yaqoob, U., Wang, Y., Wen, J., van Deursen, J., Sicard, D., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.02.015 · Cited by 240 · cited 5×
“Stiffness induces p300 nuclear accumulation and the p300-dependent transcription of the key fibrogenic genes α-smooth muscle actin (α-SMA) and connective tissue growth factor (CTGF), in addition to a panel of secreted profibrogenic and tumor-promoting factors including CXCL12, IL11, IL6, PDGFA and B, and VEGFA [45].”
BackgroundInfluentialZeybel, M., Hardy, T., Robinson, S. M., Fox, C., Anstee, Q. M., Ness, T., Masson, S., Mathers, J. C., French, J., White, S., et al. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0056-6 · Cited by 180
Histone deacetylase 4 is required for TGFβ1-induced myofibroblastic differentiation
Glenisson, W., Castronovo, V., & Waltregny, D. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.05.016 · Cited by 153
Bárcena‐Varela, M., Caruso, S., Llerena, S., Álvarez‐Sola, G., Uriarte, I., Latasa, M. U., Urtasun, R., Rebouissou, S., Alvarez, L., Jimenez, M., et al. (2019) · Hepatology · doi:10.1002/hep.30168 · Cited by 130 · cited 3×
“As previously mentioned, novel molecules with dual inhibitory capacity simultaneously targeting DNMT1 and the HMT G9a have demonstrated efficacy in reducing HSCs proliferation and impairing TGFβ mediated activation [81].”
BackgroundSelf-citationTranscriptional regulation of hepatic stellate cells
Mann, J., & Mann, D. A. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.011 · Cited by 119 · cited 1×
“Epigenetic events that control HSC activation and function are highly dynamic processes and the phenotypic conversion requires changes in expression of hundreds of different genes [19].”
BackgroundRombouts, K. (2002) · Experimental Cell Research · doi:10.1006/excr.2002.5577 · Cited by 111
Essential role of MeCP2 in the regulation of myofibroblast differentiation during pulmonary fibrosis
Hu, B., Gharaee-Kermani, M., Wu, Z., & Phan, S. H. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.01.002 · Cited by 102 · cited 1×
“MeCP2-deficient mice were found to be protected from liver [67] and lung fibrosis [76], whereas MeCP2 was found to also be implicated in myofibroblast differentiation in the heart [77] and eye [78], indicating that it could be a generic core-regulator of tissue fibrosis.”
BackgroundOrigin and function of myofibroblasts in the liver
Schwabe, R., & Wells, R. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1550061 · Cited by 86
Martin-Mateos, R., De Assuncao, T. M., Arab, J. P., Jalan-Sakrikar, N., Yaqoob, U., Greuter, T., Verma, V. K., Mathison, A. J., Cao, S., Lomberk, G., et al. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.09.005 · Cited by 73
Trichostatin A inhibits collagen synthesis and induces apoptosis in keloid fibroblasts
Diao, J.-S., Xia, W.-S., Yi, C.-G., Wang, Y.-M., Li, B., Xia, W., Liu, B., Guo, S.-Z., & Sun, X.-D. (2011) · Archives of Dermatological Research · doi:10.1007/s00403-011-1140-1 · Cited by 68
PPAR Gamma and Hepatic Stellate Cells
Hazra, S., Miyahara, T., Rippe, R. A., & Tsukamoto, H. (2004) · Comparative Hepatology · doi:10.1186/1476-5926-2-s1-s7 · Cited by 66
Dong, F., Jiang, S., Li, J., Wang, Y., Zhu, L., Huang, Y., Jiang, X., Hu, X., Zhou, Q., Zhang, Z., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.11.055 · Cited by 40
Cited by
Rho, H., Terry, A. R., Chronis, C., & Hay, N. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.06.013 · Cited by 404
Khan, Z., Nath, N., Rauf, A., Emran, T. B., Mitra, S., Islam, F., Chandran, D., Barua, J., Khandaker, M. U., Idris, A. M., et al. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110117 · Cited by 246
Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg
Fernández-Barrena, M. G., Arechederra, M., Colyn, L., Berasain, C., & Avila, M. A. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100167 · Cited by 126
“Indeed, fibrogenesis is a key contributor to HCC development, and dysregulation of epigenetic circuits is central to liver fibrogenic cell activation and HCC progression.(164,165) Pharmacological interference with such circuits is therefore emerging as an alternative strategy to halt liver fibrosis, and ultimately HCC…”
BackgroundSelf-citationJain, I., Brougham-Cook, A., & Underhill, G. H. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.06.018 · Cited by 26
Targeting interleukin-17 as a novel treatment option for fibrotic diseases
Sisto, M., & Lisi, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010164 · Cited by 22
“Positive correlations in miRNA expression and IL-17 levels have been observed in different studies related to fibrotic diseases or autoimmune diseases with a fibrotic evolution of the tissue or organs involved (Table 2).”
Metadata
- Authors
- Barcena-Varela, M., Colyn, L., & Fernandez-Barrena, M. G.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-05-21
- Volume
- 20
- Issue
- 10
- Pages
- 2507
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2945609763
- Cited by
- 72
- References
- 28
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.